Notably, supplementation with exogenous cholesterol or treatment with botulin, an SREBP2 inhibitor, could overcome the B7-H3-mediated inhibition of cholesterol metabolism and ferroptosis resistance in CRC cells [48]. Here, CD276 is linked to colorectal carcinoma.